IDEX Corporation reported fourth quarter 2025 results that exceeded estimates, with earnings and revenue surprises of 3.11% and 1.99% respectively. Sales rose 4% year over year while margins expanded. The Health & Science Technologies segment showed accelerating demand, including increased orders from AI-related projects. CEO Eric D. Ashleman stated the company executed well and saw platform growth strategies deliver visible results. IDEX issued 2026 guidance calling for continued organic growth. The company closed fiscal 2025 with better-than-expected fourth quarter results, driven by progress on its purposeful evolution strategy anchored by 80/20 practices and platform initiatives. These earnings results and forward guidance contributed to the stock's price movement.
Read full analysisIDEX Corporation reported fourth quarter 2025 results that exceeded estimates, with earnings and revenue surprises of 3.11% and 1.99% respectively. Sales rose 4% year over year while margins expanded. The Health & Science Technologies segment showed accelerating demand, including increased orders from AI-related projects. CEO Eric D. Ashleman stated the company executed well and saw platform growth strategies deliver visible results. IDEX issued 2026 guidance calling for continued organic growth. The company closed fiscal 2025 with better-than-expected fourth quarter results, driven by progress on its purposeful evolution strategy anchored by 80/20 practices and platform initiatives. These earnings results and forward guidance contributed to the stock's price movement.
IDEX Corporation (IEX) is a publicly traded company in the Industrials sector.